Yuan Fan, Hu Yue, Lei Yanmei, Jin Lingna
Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan, People's Republic of China.
Health Management (Physical Examination) Center, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan, People's Republic of China.
Discov Oncol. 2024 Sep 27;15(1):480. doi: 10.1007/s12672-024-01376-4.
In recent years, prostate cancer (PCa) has seen an increasing prevalence, particularly among middle-aged and older men, positioning it as a significant health concern. Current PCa screening predominantly utilizes prostate-specific antigen (PSA) testing, digital rectal examination (DRE), and the Gleason scoring system. However, these diagnostic methods can sometimes be imprecise. Research has identified that specific microRNAs (miRNAs) exhibit altered expression levels in PCa patients, suggesting their potential as biomarkers for both diagnosis and prognosis. Furthermore, advancements in integrating miRNAs with traditional Chinese medicine (TCM) have shown promising results in PCa treatment, potentially serving as micro-markers for TCM syndrome differentiation and treatment effectiveness. Recent developments in anti-cancer therapies that target miRNAs have also been implemented in clinical settings, laying the groundwork for personalized and precise treatment strategies for PCa. This review aims to summarize the expression patterns of miRNAs in PCa patients and explore their roles in the diagnosis, treatment, and prognosis of the disease.
近年来，前列腺癌（PCa）的患病率不断上升，尤其是在中老年男性中，这使其成为一个重大的健康问题。目前的前列腺癌筛查主要采用前列腺特异性抗原（PSA）检测、直肠指检（DRE）和 Gleason 评分系统。然而，这些诊断方法有时可能不够精确。研究发现，特定的微小 RNA（miRNA）在前列腺癌患者中表现出表达水平的改变，这表明它们有可能作为诊断和预后的生物标志物。此外，将 miRNA 与传统中医（TCM）相结合的进展在前列腺癌治疗中显示出有前景的结果，有可能作为中医辨证和治疗效果的微观标志物。针对 miRNA 的抗癌疗法的最新进展也已在临床中实施，为前列腺癌的个性化和精准治疗策略奠定了基础。本综述旨在总结前列腺癌患者中 miRNA 的表达模式，并探讨它们在该疾病的诊断、治疗和预后中的作用。
